Patents by Inventor Pasi Janne

Pasi Janne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS
    Publication number: 20210078977
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 18, 2021
    Inventors: Nathanael S. GRAY, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG
  • PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20210077469
    Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: (I?), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: March 18, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • INHIBITORS OF EGFR AND METHODS OF USE THEREOF
    Publication number: 20210040088
    Abstract: The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: February 11, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Pyrimidines as EGFR inhibitors and methods of treating disorders
    Patent number: 10870636
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 22, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Pasi Janne, Hwan Geun Choi, Jaebong Jang
  • INHIBITORS OF EGFR AND METHODS OF USE THEREOF
    Publication number: 20200390783
    Abstract: The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 17, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Non-invasive blood based monitoring of genomic alterations in cancer
    Patent number: 10865451
    Abstract: The invention provides methods to monitor cell free nucleic acids.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: December 15, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Pasi A. Janne, Cloud P. Paweletz, Geoffrey Oxnard, Yanan Kuang
  • DEGRADERS OF EGFR AND METHODS OF USE THEREOF
    Publication number: 20200377501
    Abstract: The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • DEGRADERS OF EGFR AND METHODS OF USE THEREOF
    Publication number: 20200377477
    Abstract: The application relates to a compound having Formula (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a N pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200375999
    Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: (I?), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Inhibitors of EGFR and methods of use thereof
    Patent number: 10836722
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: November 17, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Michael Eck, Pasi Janne, Hwan Geun Choi, Jaebong Jang, Kwok-Kin Wong
  • 6,11-DIHYDRO-5H-BENZO[B]CARBAZOLE INHIBITORS OF ALK AND SRPK AND METHODS OF USE
    Publication number: 20200223798
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Application
    Filed: October 30, 2019
    Publication date: July 16, 2020
    Inventors: John HATCHER, Nathanael S. GRAY, Hwan Geun CHOI, Pasi JANNE, Tinghu ZHANG
  • BIFUNCTIONAL MOLECULES FOR HER3 DEGRADATION AND METHODS OF USE
    Publication number: 20200216454
    Abstract: The invention provides bifunctional compounds which act as protein degradation inducing moieties for a HER family protein, such as Her3. The invention also provides methods for the targeted degradation of a HER family protein through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to the HER family protein which can be utilized in the treatment of disorders modulated by a HER family protein.
    Type: Application
    Filed: December 29, 2016
    Publication date: July 9, 2020
    Inventors: Nathanael S. GRAY, James BRADNER, Pasi JANNE, Jaebong JANG, Dennis BUCKLEY, Dennis DOBROVOLSKY
  • INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE
    Publication number: 20200199121
    Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.
    Type: Application
    Filed: August 31, 2018
    Publication date: June 25, 2020
    Inventors: JOHN M. HATCHER, NATHANAEL S. GRAY, JAEBONG JANG, DRIES DE CLERCQ, PASI JANNE, JAMES A. SAXON, MICHAEL ECK, DAVID A. SCOTT, ALYSSA VERANO
  • Pyrimidines as EGFR inhibitors and methods of treating disorders
    Patent number: 10550112
    Abstract: The application relates to a compound having Formula (I?): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: February 4, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Jaebong Jang, Pasi Janne
  • INHIBITORS OF EGFR AND METHODS OF USE THEREOF
    Publication number: 20200002279
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: June 13, 2019
    Publication date: January 2, 2020
    Inventors: Nathanael S. GRAY, Michael ECK, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG, Kwok-Kin WONG
  • Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK
    Patent number: 10508082
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 17, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: John Hatcher, Nathanael S. Gray, Hwan Geun Choi, Pasi Janne, Tinghu Zhang
  • Bifunctional molecules for degradation of EGFR and methods of use
    Patent number: 10450310
    Abstract: The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 22, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Jaebong Jang, Dries De Clercq, Michael Eck, Pasi Janne
  • Inhibitors of EGFR and methods of use thereof
    Patent number: 10385019
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 20, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Michael Eck, Pasi Janne, Hwan Geun Choi, Jaebong Jang, Kwok-Kin Wong
  • NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS
    Publication number: 20190194169
    Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: March 1, 2019
    Publication date: June 27, 2019
    Inventors: Nathanael S. GRAY, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG
  • Hydrophobically tagged small molecules as inducers of protein degradation
    Patent number: RE48175
    Abstract: Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L1 represents a linker; and RH represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 25, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Yale University
    Inventors: Nathanael Gray, Ting Xie, Sang Min Lim, Pasi A. Janne, Craig M. Crews